33 results
8-K
EX-3.1
VRDN
Viridian Therapeutics, Inc.
18 Dec 23
Amendments to Articles of Incorporation or Bylaws
8:15am
8-K
EX-3.1
VRDN
Viridian Therapeutics, Inc.
2 Nov 23
Departure of Directors or Certain Officers
4:31pm
10-K
2021 FY
EX-3.1
VRDN
Viridian Therapeutics, Inc.
Annual report
11 Mar 22
8:11am
8-K
EX-3.1
l0f149kyem3b j7vd0
23 Sep 21
Entry into a Material Definitive Agreement
4:30pm
8-K/A
EX-3.1
18yh6 2cb
15 Jun 21
Amendments to Articles of Incorporation or Bylaws
5:30pm
8-K
EX-3.3
wpu yx0mj4mv0v3
20 Jan 21
Departure of Directors or Certain Officers
8:01am
8-K
EX-3.1
dwec5k
20 Jan 21
Departure of Directors or Certain Officers
8:01am
8-K
EX-3.2
hdsgrkfbes38ne9 g4n
20 Jan 21
Departure of Directors or Certain Officers
8:01am
8-K
EX-3.1
7wlmmcnb3hi7un2nrr
4 Jan 21
Amendments to Articles of Incorporation or Bylaws
4:16pm
8-K
EX-3.1
8kbpej
13 Nov 20
Amendments to Articles of Incorporation or Bylaws
4:15pm
8-K
EX-3.1
imx 751xf
28 Oct 20
Acquisition includes clinical stage anti-IGF-1R monoclonal antibody, VRDN-001, intended for Company plans to use private placement financing proceeds of $91 million to advance multiple
9:28am
8-K
EX-3.2
nq0h5 057g
13 Feb 17
Completion of Acquisition or Disposition of Assets
12:00am
8-K
EX-3.1
ht5eijqdjdi
13 Feb 17
Completion of Acquisition or Disposition of Assets
12:00am
8-K
EX-3.4
f9fozs0vwdrttil06
13 Feb 17
Completion of Acquisition or Disposition of Assets
12:00am
8-K
EX-3.3
54j1t3pqwht sgsi7v
13 Feb 17
Completion of Acquisition or Disposition of Assets
12:00am
S-4
EX-3.3
c0c7 mdt86
2 Dec 16
Registration of securities issued in business combination transactions
12:00am
8-K
EX-3.1
dr2ts 9fmq
1 Nov 16
Entry into a Material Definitive Agreement
12:00am
425
EX-3.1
ud2h5u0i
1 Nov 16
Business combination disclosure
12:00am